V600E
· 6 retained evidence mentions
Source-grounded findings
Supporting evidence
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| variant | V600E | “Recently, immunohistochemistry (IHC) with anti-BRAF V600E (VE1) antibody has increased practical utility and implemented clinically for the detection of BRAFV600E mutation.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “V600E (c.1799T > A) was the predominant mutation, found in 61/63 (96.8%) cases.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “V600E was the predominant mutation type, found in 96.3% of the cases.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Overall, BMR was 62.4% (131/210) with V600E mutation accounting for 98.5% of cases.” | 0.82 | literature_variant_regex_v2 |
| variant | V600E | “Most of the cases showed the common V600E mutation.” | 0.82 | literature_variant_regex_v2 |